30 Aug 2017 07:00
30 August 2017
Motif Bio plc
("Motif" or the "Company")
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it was informed on 29 August 2017 by Amphion Innovations plc ("Amphion") that 1,700,000 ordinary shares in the Company had been sold in respect of a partial repayment of a loan facility. Following this sale, Amphion holds 41,540,645 ordinary shares of Motif Bio, representing 15.8% of the issued share capital. Further details of Amphion's loan facility, which is secured by a pledge over Amphion's interest in a total of 40,761,625 ordinary shares in Motif Bio, may be found in an RNS announcement released by Amphion today. The TR-1 disclosure is set out below.
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi | ||||
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii | Motif Bio plc | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | X | |||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
An event changing the breakdown of voting rights | ||||
Other (please specify): | ||||
3. Full name of person(s) subject to thenotification obligation: iii |
Amphion Innovations plc
| |||
4. Full name of shareholder(s) (if different from 3.):iv | ||||
5. Date of the transaction and date onwhich the threshold is crossed orreached: v | August 25 2017
| |||
6. Date on which issuer notified: | August 29 2017 | |||
7. Threshold(s) that is/are crossed orreached: vi, vii | 16% | |||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares viii, ix | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights x | ||||||||||||
Direct, | Direct xi | Indirect xii | Direct | Indirect | ||||||||||||
GB00BVVT4H71 | 43,240,645 | 43,240,645 |
41,540,645
|
41,540,645
| 15.8% | |||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate xiii | Exercise/Conversion Period xiv | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
| ||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date xvii | Exercise/Conversion period xviii | Number of voting rights instrument refers to
| % of voting rights xix, xx
| |||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
41,540,645 | 15.8% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi | ||
| ||
Proxy Voting: | ||
10. Name of the proxy holder: | ||
11. Number of voting rights proxy holder will ceaseto hold: | ||
12. Date on which proxy holder will cease to holdvoting rights: | ||
13. Additional information: |
| |
14. Contact name: | Charlie Morgan | |
15. Contact telephone number: | +1 (212) 210 6224 | |